Avrobio Inc (AVRO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

ONE KENDALL SQUARE CAMBRIDGE, MA 02139

AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Its ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, its foundation designed to deliver gene therapy worldwide. The company is headquartered in Cambridge, Mass., with an office in Toronto, Ontario.

Data as of 2021-10-17 10:23:53 -0400
Market Cap253.014 Million Shares Outstanding43.623 Million Avg 30-day Volume255.189 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-2.11 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.59314 52-week High/Low20.07 / 5.23 Next Earnings Date2021-11-04 Price to Cash FLow (P/CF) -8.3966
Data provided by IEX Cloud

Are you looking for this stock instead?

View SEC Filings from AVRO instead.

View recent insider trading info

Funds Holding AVRO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVRO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

VICKERS PHILIP J.

  • Director
4,800 2021-07-07 2

DONENBERG PHILLIP B.

  • Director
17,438 2021-06-10 2

CLARK IAN T

  • Director
17,438 2021-06-10 1

BOOTH BRUCE

  • Director
17,438 2021-06-10 1

PETERSEN DEANNA M CHIEF BUSINESS OFFICER

  • Officer
125,000 2021-06-10 2

FARFEL GAIL M

  • Director
17,438 2021-06-10 1

JENKINS ANNALISA

  • Director
17,438 2021-06-10 1

MACKAY GEOFFREY PRESIDENT & CEO

  • Officer
  • Director
125,000 2021-06-10 3

PAIGE CHRISTOPHER

  • Director
17,438 2021-06-10 1

AVRUCH STEVEN CHIEF LEGAL OFFICER

  • Officer
125,000 2021-06-10 2

OSTROWSKI ERIK CHIEF FINANCIAL OFFICER

  • Officer
125,000 2021-06-10 2

ESCOLAR DIANA CHIEF MEDICAL OFFICER

  • Officer
50,000 2021-06-10 3

MASON CHRISTOPHER CHIEF SCIENTIFIC OFFICER

  • Officer
125,000 2021-06-10 2

VOLCK BIRGITTE PRESIDENT OF R&D

  • Officer
0 2020-03-04 0

ATLAS VENTURE ASSOCIATES X, L.P.

  • 10% Owner
3,710,052 2020-02-13 0

ATLAS VENTURE FUND X, L.P.

ATLAS VENTURE ASSOCIATES X, L.P.

ATLAS VENTURE ASSOCIATES X, LLC

  • 10% Owner
4,756,478 2019-07-19 0

ATLAS VENTURE OPPORTUNITY FUND I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC

  • SEE REMARKSSEE REMARKSSEE REMARKS
810,811 2019-07-19 0

CLARUS LIFESCIENCES III, L.P.

CLARUS VENTURES III GP, L.P.

  • 10% Owner
No longer subject to file 2019-05-20 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
AVROBIO INC AVRO 2021-10-21 15:15:03 UTC -0.2983 0.3683 950000
AVROBIO INC AVRO 2021-10-21 14:45:03 UTC -0.212 0.282 950000
AVROBIO INC AVRO 2021-10-21 14:15:03 UTC -0.212 0.282 950000
AVROBIO INC AVRO 2021-10-21 13:45:03 UTC -0.212 0.282 950000
AVROBIO INC AVRO 2021-10-21 13:15:02 UTC -0.212 0.282 950000
AVROBIO INC AVRO 2021-10-21 12:45:03 UTC -0.212 0.282 950000
AVROBIO INC AVRO 2021-10-20 22:15:03 UTC -0.212 0.282 1000000
AVROBIO INC AVRO 2021-10-20 21:45:03 UTC -0.212 0.282 1000000
AVROBIO INC AVRO 2021-10-20 21:15:03 UTC -0.212 0.282 1000000
AVROBIO INC AVRO 2021-10-20 20:45:03 UTC -0.2531 0.3231 1000000
AVROBIO INC AVRO 2021-10-20 20:15:03 UTC -0.2531 0.3231 1000000
AVROBIO INC AVRO 2021-10-20 19:45:04 UTC -0.2531 0.3231 1000000
AVROBIO INC AVRO 2021-10-20 19:15:03 UTC -0.2531 0.3231 1000000
AVROBIO INC AVRO 2021-10-20 18:45:03 UTC -0.3011 0.3711 1000000
AVROBIO INC AVRO 2021-10-20 18:15:04 UTC -0.3011 0.3711 1000000
AVROBIO INC AVRO 2021-10-20 17:45:03 UTC -0.3011 0.3711 1000000
AVROBIO INC AVRO 2021-10-20 17:15:03 UTC -0.3011 0.3711 1000000
AVROBIO INC AVRO 2021-10-20 16:45:03 UTC -0.3011 0.3711 1000000
AVROBIO INC AVRO 2021-10-20 16:15:04 UTC -0.3011 0.3711 1000000
AVROBIO INC AVRO 2021-10-20 15:45:03 UTC -0.3011 0.3711 1000000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund AVRO -58.0 shares, $-902.48 2020-03-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund AVRO -3.0 shares, $-46.68 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund AVRO -34.0 shares, $-529.04 2020-03-31 N-PORT

Elevate your investments